Moderna & COVID-19 Vaccine Stocks Surge in 2025 Amid Booster Campaign and Rising Cases - Prices Soar
In 2025, shares of leading COVID-19 vaccine manufacturers like Moderna and Novavax have surged significantly as the U.S. government encourages booster vaccinations to combat emerging variants and rising infection rates.
In 2024, shares of major COVID-19 vaccine producers such as Moderna (MRNA) and Novavax (NVAX) experienced a sharp increase following announcements from the Biden administration promoting booster shots for the upcoming fall season amid the rise of new virus subvariants.
Highlights
- Stock prices of Moderna, BioNTech, and Novavax jumped considerably after news of the government's booster shot initiative.
- Emergence of new COVID-19 subvariants has accelerated development and deployment of updated booster vaccines targeting these strains.
- Despite recent gains, all three vaccine makers have seen stock declines year-to-date, reflecting broader market challenges.
Moderna’s shares surged by 9.3%, while BioNTech’s American depositary receipts (ADRs), partnered with Pfizer (PFE), rose 6.5%. Novavax, known for its protein-based COVID-19 vaccine, initially jumped 18% before settling with a 13% increase.
Amid rising cases and evolving variants, vaccine manufacturers are focusing on boosters tailored to new strains. In June 2024, the U.S. FDA recommended booster shots targeting the XBB.1.5 omicron subvariant. More recently, the EG.5 variant, dubbed “Eris,” has become dominant across the U.S., with the WHO also tracking the BA.2.86 strain.
Despite Monday’s positive movement, the vaccine makers’ stocks remain below their earlier 2024 levels, with BioNTech and Novavax down approximately 20% year-to-date, and Moderna falling 37%. These declines contrast with the broader S&P 500 healthcare sector, which has decreased by roughly 2% during the same timeframe.
For news tips or inquiries, please contact Investopedia at tips@investopedia.com.
Discover engaging topics and analytical content in Company News as of 26-08-2023. The article titled " Moderna & COVID-19 Vaccine Stocks Surge in 2025 Amid Booster Campaign and Rising Cases - Prices Soar " provides new insights and practical guidance in the Company News field. Each topic is meticulously analyzed to deliver actionable information to readers.
The topic " Moderna & COVID-19 Vaccine Stocks Surge in 2025 Amid Booster Campaign and Rising Cases - Prices Soar " helps you make smarter decisions within the Company News category. All topics on our website are unique and offer valuable content for our audience.